
|Videos|January 19, 2023
Efficacy and Safety of JAK inhibitors for AD
Author(s)Brett King, MD, PhD, Alexandra K. Golant, MD
Experts in atopic disease management review the efficacy and safety data of the JAK inhibitor class, highlighting the importance of time to treatment response and itch reduction.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Dermalogica Enters Medical Aesthetics with FDA-Cleared Microneedling PRO Pen
2
Social Media Mythbusters: Hypochlorous Acid Sprays
3
Quoin Submits First-Ever IND Application for Peeling Skin Syndrome Therapy
4
Topical GX-03 Hits 92.6% EASI-50 at Week 4 in Phase 2 AD Interim
5


















